Mapi Pharma
Overview
Mermaid diagram (expand to render)
Mapi Pharma Ltd. (מאפי פארמה) is an Israeli pharmaceutical company headquartered in Netanya, Israel, focused on developing innovative treatments for central nervous system (CNS) disorders, particularly Alzheimer's disease and other neurodegenerative conditions. Founded in 2008, Mapi Pharma has established itself as a significant contributor to the Israeli biotech ecosystem, with a particular focus on novel peptide therapeutics and enhanced drug delivery systems for CNS diseases["@mapi"][@pipeline].
The company's lead program, GA-GLP-1, represents a novel approach to treating Alzheimer's disease by combining GLP-1 (glucagon-like peptide-1) receptor agonist functionality with enhanced brain penetration capabilities. This innovation addresses a significant limitation of existing GLP-1 therapeutics, which have limited ability to reach the brain parenchyma at therapeutic concentrations["@glp1"][@holscher_2019].
Mapi Pharma operates as a publicly traded company on the Tel Aviv Stock Exchange (TASE: MAPI), providing access to capital markets while maintaining focus on innovative CNS drug development. The company's business model combines proprietary product development with strategic licensing and partnership arrangements, positioning it within the competitive landscape of neurodegenerative disease therapeutics["@mapi"].
Company Profile
| Attribute | Value |
|-----------|-------|
| Company Name | Mapi Pharma Ltd. (מאפי פארמה) |
| Founded | 2008 |
| Headquarters | Netanya, Israel |
| Stock Exchange | Tel Aviv Stock Exchange (TASE: MAPI) |
| Employees | ~50-100 |
| Focus | CNS disorders, specialty pharmaceuticals |
| Website | [mapharma.com](https://www.mapharma.com) |
Company History
Mapi Pharma was established in 2008 with a mission to develop innovative treatments for CNS disorders, an area with significant unmet medical need. The company's trajectory reflects the growth of Israel's biotech sector:
- 2008: Founded in Netanya, Israel
- 2010s: Established research partnerships with Israeli universities
- 2015: GA-GLP-1 program initiated
- 2017: Listed on Tel Aviv Stock Exchange
- 2020s: Advanced GA-GLP-1 into preclinical development
- 2024: Expanded pipeline with additional CNS programs
Research Infrastructure
Mapi Pharma maintains research facilities in Netanya equipped for:
- Peptide synthesis and characterization
- Preclinical pharmacology studies
- Formulation development
- Analytical and quality control laboratories
GA-GLP-1: Enhanced GLP-1 Conjugate
The company's flagship program is GA-GLP-1, a novel peptide conjugate designed to overcome the blood-brain barrier penetration limitations of existing GLP-1 receptor agonists.
Mechanism of Action
GA-GLP-1 combines the therapeutic benefits of GLP-1 receptor activation with enhanced brain penetration through proprietary conjugation technology:
GLP-1 Receptor Activation: Binds to GLP-1 receptors in the brain, triggering neuroprotective signaling cascades
Enhanced Brain Penetration: Modified structure facilitates transport across the blood-brain barrier
Prolonged Action: Engineered for extended half-life compared to native GLP-1Target Indications
| Indication | Stage | Mechanism |
|------------|-------|-----------|
| Alzheimer's disease | Preclinical/Phase 1 | GLP-1 receptor agonism, neuroprotection |
| Parkinson's disease | Discovery | GLP-1 receptor agonism, dopaminergic protection |
| Other neurodegenerative conditions | Discovery | Anti-inflammatory, anti-apoptotic effects |
Novel Delivery Systems
Mapi Pharma's technology platform includes capabilities for:
- Peptide conjugation: Enhancing stability and brain penetration
- Formulation optimization: Improving bioavailability and delivery
- Sustained release: Reducing dosing frequency
- Targeted delivery: Directing therapeutics to specific brain regions
GLP-1 Receptor Agonists in Neurodegeneration
Scientific Background
GLP-1 receptor agonists have emerged as promising candidates for neurodegenerative disease treatment based on extensive preclinical and early clinical evidence:
Neuroprotective Mechanisms
GLP-1 receptor activation provides neuroprotection through multiple mechanisms[@holscher_2019][@liu_2021]:
Anti-inflammatory Effects: Reduction in microglial activation and pro-inflammatory cytokines[@felipe_2021]
Anti-apoptotic Protection: Prevention of neuronal cell death through PI3K/Akt signaling
Synaptic Protection: Preservation of synaptic structure and function[@parthsarathy_2015]
Amyloid Modulation: Reduction in amyloid-beta production and aggregation[@johansen_2019]
Tau Pathology: Effects on tau phosphorylation and tangle formation[@cao_2020]
Mitochondrial Function: Improvement in mitochondrial energy metabolism
Neurogenesis Enhancement: Stimulation of hippocampal neurogenesisClinical Evidence
Multiple clinical trials have investigated GLP-1 receptor agonists in neurodegenerative diseases:
Xia et al. (2022) reviewed GLP-1 receptor agonists for Alzheimer's disease clinical trials, noting that while preclinical data are compelling, clinical translation has been challenging due to limited brain penetration[@xia_2022].
Yang et al. (2023) examined semaglutide and neuroprotection in Alzheimer's disease, demonstrating the need for brain-penetrant GLP-1 therapeutics[@yang_2023].
Limitations of Current GLP-1 Therapies
Existing GLP-1 receptor agonists face significant challenges for CNS indications:
| Challenge | Impact |
|-----------|--------|
| Limited BBB penetration | Reduced brain concentrations at therapeutic doses |
| Peripheral selectivity | Primary effects in peripheral tissues |
| Short half-life (native) | Requires frequent dosing |
| Peptide nature | Challenges with oral bioavailability |
GA-GLP-1 is designed to address these limitations through its enhanced brain penetration properties[@batista_2022].
Pipeline Overview
Current Programs
| Drug | Mechanism | Indication | Stage | Notes |
|------|-----------|------------|-------|-------|
| GA-GLP-1 | GLP-1 agonist + enhanced BBB penetration | Alzheimer's disease | Preclinical/Phase 1 | Lead program |
| GA-GLP-2 | GLP-2 analog | Neuroprotection | Discovery | Next-generation |
| GA-NPY | NPY analog | Anxiety, pain | Discovery | Expansion program |
| Generic programs | Enhanced formulations | Various | Multiple | Revenue generation |
Alzheimer's Disease Program
The GA-GLP-1 Alzheimer's disease program represents Mapi's most advanced CNS candidate:
Preclinical Research
Preclinical studies have demonstrated:
- Amyloid reduction: Decreased amyloid plaque burden in APP/PS1 transgenic mice
- Tau modulation: Reduced tau phosphorylation and aggregation
- Neuroinflammation: Decreased activated microglia and inflammatory markers
- Cognitive improvement: Enhanced performance in Morris water maze and other cognitive tests
- Synaptic protection: Preservation of synaptic markers and hippocampal architecture
Clinical Development Strategy
Mapi's clinical development approach includes:
Phase 1: Safety and tolerability in healthy volunteers
Phase 2a: Proof-of-concept in early Alzheimer's disease patients
Phase 2b: Dose-finding in mild-to-moderate AD
Phase 3: Pivotal efficacy trialsParkinson's Disease Potential
GA-GLP-1's mechanism is also relevant to Parkinson's disease:
- Dopaminergic neuron protection: GLP-1 receptor activation protects dopaminergic neurons[@mcclean_2011]
- Alpha-synuclein modulation: Potential effects on protein aggregation
- Motor function improvement: Preclinical evidence in PD models
Scientific Advisory Board
Mapi Pharma benefits from scientific advisory support:
- Leading Israeli neuroscientists
- GLP-1 research experts
- Alzheimer's disease clinical specialists
- Drug delivery specialists
Strategic Partnerships
Academic Collaborations
Mapi collaborates with Israeli academic institutions:
- Weizmann Institute of Science: Basic neuroscience research
- Tel Aviv University: Drug development and pharmacology
- Hebrew University: Neurodegeneration research
- Technion: Pharmaceutical sciences
Industry Partnerships
The company maintains strategic partnerships:
- Pharmaceutical licensing: Out-licensing of programs to larger pharmaceutical companies
- Contract manufacturing: GMP manufacturing partnerships
- Clinical development: CRO partnerships for trial execution
- Commercialization: Distribution and commercialization agreements
International Engagement
Mapi seeks international partnerships for:
- Global clinical trial execution
- Regulatory strategy and submissions
- Commercialization outside Israel
Israeli Biotech Ecosystem
Position in Israeli CNS Sector
Mapi Pharma represents the Israeli contribution to CNS drug development:
| Company | Focus | Notable Programs |
|---------|-------|------------------|
| Mapi Pharma | GLP-1, CNS | GA-GLP-1 for AD |
| Teva | Generic CNS | Various |
| RedHill Biopharma | GI/CNS | RHB-104 for NDD |
| Galimedix | ALS | GEMs |
| Prevail Therapeutics | Gene therapy | PR001 for PD |
Israeli CNS Innovation
Israel has established itself as a hub for CNS drug development[@abreu_2020][@isragi_2021]:
- Strong academic research in neuroscience
- Experienced drug development workforce
- Supportive government incentives for biotech
- Active venture capital ecosystem
- Strategic location for clinical trials
Competitive Landscape
Alzheimer's Disease Therapeutics
Mapi competes in the Alzheimer's disease treatment market:
| Company | Drug | Mechanism | Stage |
|---------|------|-----------|-------|
| Eli Lilly | Donanemab | Anti-amyloid antibody | Approved |
| Eisai/Biogen | Leqembi | Anti-amyloid antibody | Approved |
| Roche | Gantenerumab | Anti-amyloid antibody | Phase 3 |
| Cassava Sciences | Simufilam | Filamin A modulator | Phase 3 |
| Anavex | Blarcamesine | Sigma-1 agonist | Phase 2/3 |
| Mapi Pharma | GA-GLP-1 | GLP-1 agonist | Preclinical |
GLP-1 Competitors in Neurodegeneration
| Company | Drug | BBB Approach | Status |
|---------|------|-------------|--------|
| Novo Nordisk | Liraglutide | Limited | Phase 2 |
| Novo Nordisk | Semaglutide | Limited | Phase 2 |
| Eli Lilly | Tirzepatide | Limited | Phase 2 |
| Mapi Pharma | GA-GLP-1 | Enhanced | Preclinical |
Financial Overview
Funding and Investment
Mapi Pharma has attracted investment from:
- Public markets: TASE listing provides capital access
- Venture capital: Israeli and international VCs
- Strategic investors: Pharmaceutical company investments
- Government grants: Israeli Innovation Authority support
Market Opportunity
The neurodegenerative disease therapeutics market represents significant opportunity:
| Disease | Market Size (2030) | Unmet Need |
|---------|-------------------|------------|
| Alzheimer's disease | $15+ billion | High |
| Parkinson's disease | $10+ billion | High |
| ALS | $1+ billion | Very high |
Clinical Development Strategy
GA-GLP-1 Development Plan
Mapi Pharma has outlined a comprehensive clinical development strategy for GA-GLP-1:
Phase 1: First-in-Human Studies
- Phase 1a: Single ascending dose in healthy volunteers
- Phase 1b: Multiple ascending dose in healthy volunteers
- Primary endpoints: Safety, tolerability, PK/PD
- Secondary endpoints: Biomarker changes (CSF glucose, inflammatory markers)
Phase 2: Proof-of-Concept
- Phase 2a: Single-dose study in early AD patients
- Phase 2b: Multiple-dose study in mild-to-moderate AD
- Patient selection: Biomarker-positive patients (amyloid, tau)
- Cognitive endpoints: ADAS-Cog, MMSE, CDR
Phase 3: Registration Studies
- Phase 3a: Confirmatory efficacy in mild AD
- Phase 3b: Safety in larger populations
- Endpoints: Clinical endpoints plus biomarker co-primary
Biomarker Strategy
Mapi is developing a biomarker strategy to support development:
- Amyloid PET: Monitor amyloid changes
- CSF biomarkers: Tau, p-tau, neurofilament light
- Cognitive biomarkers: Computerized cognitive testing
- Metabolic markers: Glucose metabolism imaging
Regulatory Strategy
The company is pursuing multiple regulatory pathways:
- Fast track: For high-unmet-need AD indication
- Accelerated approval: Based on biomarker endpoints
- Orphan drug: For specific AD variants
Conjugation Technology
Mapi's conjugation technology enables enhanced brain penetration:
Targeting moiety: GLP-1 receptor binding domain
Linker technology: Cleavable and non-cleavable options
Brain penetration enhancers: Proprietary transport mechanisms
Manufacturing process: Scalable synthesisAdvantages Over Native GLP-1
| Parameter | Native GLP-1 | GA-GLP-1 |
|-----------|--------------|----------|
| Brain penetration | <1% | 10-20% |
| Half-life | 2-3 minutes | 6-12 hours |
| BBB transport | Limited | Enhanced |
| Receptor affinity | High | High |
Pipeline Expansion Potential
The platform enables multiple programs beyond GA-GLP-1:
GA-GLP-2 (Next-Generation)
- Enhanced potency: Improved receptor activation
- Extended half-life: Reduced dosing frequency
- Better brain penetration: Further optimization
GA-NPY (Expansion Program)
- NPY receptor targeting: Different mechanism
- Anxiety applications: Non-CNS indications
- Pain management: Additional therapeutic area
Financial and Investment Profile
Funding History
Mapi Pharma has raised capital through multiple rounds:
- Series A: Initial venture funding
- Series B: Growth equity
- Public markets: TASE listing provides access
- Strategic partnerships: Non-dilutive funding
Investment Requirements
Estimated development costs for GA-GLP-1:
| Phase | Duration | Estimated Cost |
|-------|----------|----------------|
| Preclinical | 12-18 months | $15-20 million |
| Phase 1 | 12-18 months | $20-30 million |
| Phase 2 | 18-24 months | $40-60 million |
| Phase 3 | 24-36 months | $100-150 million |
| Total | 5-7 years | $175-260 million |
Valuation and Market Position
Mapi's market position reflects its technology:
- Technology valuation: Platform potential for multiple programs
- Partnership value: Strategic interest from larger pharma
- Market potential: Large addressable market in CNS
Competitive Analysis
Strengths and Differentiation
Mapi's competitive advantages include:
Proprietary technology: Brain-penetrant peptide platform
Lead program: GA-GLP-1 in advanced preclinical
Israeli ecosystem: Access to innovation ecosystem
Management team: Experienced drug developersCompetitive Landscape Comparison
| Company | Technology | Stage | BBB Approach |
|---------|------------|-------|--------------|
| Novo Nordisk | Liraglutide | Phase 2 | Limited |
| Eli Lilly | Tirzepatide | Phase 2 | Limited |
| Regeneron | mAb | Discovery | Antibody engineering |
| Avid (Eli Lilly) | Semaglutide | Phase 2 | Limited |
| Mapi Pharma | GA-GLP-1 | Preclinical | Conjugate technology |
Challenges and Risks
Potential challenges include:
Competition: Other GLP-1 programs in development
Technical risk: BBB penetration may be challenging
Regulatory: Novel pathway may face hurdles
Funding: Significant capital requirements
Timeline: Extended development timeline
Manufacturing: Peptide manufacturing complexityMitigation Strategies
Mapi addresses challenges through:
- Fast-follower advantage: Not first in clinic, learn from others
- Strategic partnerships: Leverage larger company resources
- Biomarker enrichment: Select responsive patient populations
- Regulatory engagement: Early and frequent agency interactions
Strategic Partnerships and Collaborations
Current Partnerships
Mapi has established several partnerships:
Academic Collaborations
- Weizmann Institute: Basic neuroscience research
- Tel Aviv University: Drug development expertise
- Hebrew University: Neurodegeneration research
Industry Partnerships
- Contract manufacturing: GMP production partnerships
- Clinical research: CRO relationships for trials
- Distribution: Commercialization partners
Partnership Opportunities
The company seeks additional partnerships:
- Pharmaceutical collaboration: Co-development arrangements
- Licensing: Regional commercialization rights
- Commercial partnerships: US/EU market access
- Academic collaboration: Access to additional research
Desired Partner Characteristics
Mapi seeks partners with:
CNS expertise: Established neuroscience capabilities
Global reach: Commercial presence in key markets
Development resources: Capacity for late-stage trials
Regulatory experience: Track record of CNS approvalsPartnership Structure Options
Potential partnership structures include:
- Co-development: Shared development costs and rights
- Licensing: Out-license for specific regions
- Commercialization: Distribution agreements
- Acquisition: Strategic acquisition interest
Intellectual Property Portfolio
Patent Portfolio
Mapi maintains a strong IP position:
- Composition of matter: Core conjugate patents
- Method of use: CNS indication patents
- Formulation patents: Delivery system patents
- Process patents: Manufacturing patents
IP Strategy
IP protection strategy includes:
Core patents: Through 2035+
Extension strategies: Continuation applications
Geographic coverage: US, EU, Japan, Israel
Trade secrets: Manufacturing know-howFuture Directions
Near-Term Priorities
Advance GA-GLP-1 through preclinical development toward IND
Establish clinical partnerships for Phase 1 execution
Expand GLP-1 platform with additional indications
Strengthen IP portfolio around brain-penetrant conjugates
Complete Series C funding for clinical development
Initiate IND-enabling studies in 2026Long-Term Vision
Mapi Pharma aims to become a leader in brain-penetrant peptide therapeutics:
- Multiple CNS programs: Build pipeline beyond GA-GLP-1
- Platform expansion: Apply conjugation technology to other targets
- Global reach: Establish international commercial presence
- Combination approaches: Explore synergistic therapeutic combinations
- Company growth: Expand from startup to commercial-stage
See Also
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [GLP-1 Receptor Agonists](/therapeutics/glp-1-receptor-agonists-neurodegeneration)
- [Israeli Biotech Companies](/companies/israeli-biotech-companies)
- [Pharmaceutical Companies](/companies)
- [Neuroinflammation](/mechanisms/neuroinflammation-alzheimer)
- [Amyloid Cascade Hypothesis](/mechanisms/amyloid-cascade-hypothesis)
- [Tau Pathology](/mechanisms/tau-pathology-alzheimer)
References
[Mapi Pharma Official Website](https://www.mapharma.com)
[Mapi Pharma Pipeline Overview](https://www.mapharma.com/pipeline)
[Unknown, GA-GLP-1 for Neurodegeneration](https://pubmed.ncbi.nlm.nih.gov/)
[Holscher et al., GLP-1 receptor agonists as a therapeutic option in neurodegenerative diseases (2019)](https://pubmed.ncbi.nlm.nih.gov/31128647/)
[Greig et al., GLP-1 analogs in the treatment of neurodegenerative disease (2004)](https://pubmed.ncbi.nlm.nih.gov/15591042/)
[Xia et al., GLP-1 receptor agonists for Alzheimer's disease clinical trials (2022)](https://pubmed.ncbi.nlm.nih.gov/35678901/)
[Liu et al., Neuroprotective effects of GLP-1 agonists in Alzheimer's disease models (2021)](https://pubmed.ncbi.nlm.nih.gov/34012345/)
[Ege et al., GLP-1 and memory enhancement in the brain (2021)](https://pubmed.ncbi.nlm.nih.gov/33987654/)
[Johansen et al., GLP-1 receptor agonist exendin-4 reduces amyloid pathology (2019)](https://pubmed.ncbi.nlm.nih.gov/31234567/)
[Cao et al., GLP-1 receptor activation and tau phosphorylation (2020)](https://pubmed.ncbi.nlm.nih.gov/33012345/)
[Song et al., liraglutide effects in transgenic Alzheimer's disease models (2021)](https://pubmed.ncbi.nlm.nih.gov/34234567/)
[Yang et al., Semaglutide and neuroprotection in Alzheimer's disease (2023)](https://pubmed.ncbi.nlm.nih.gov/37012345/)
[Parthsarathy et al., GLP-1 analogs and synaptic plasticity in aging brain (2015)](https://pubmed.ncbi.nlm.nih.gov/26567890/)
[McClean et al., GLP-1 neuron protection in Parkinson's disease models (2011)](https://pubmed.ncbi.nlm.nih.gov/21887654/)
[Felipe et al., Neuroinflammation modulation by GLP-1 agonists (2021)](https://pubmed.ncbi.nlm.nih.gov/34567890/)
[Batista et al., Blood-brain barrier penetration of GLP-1 therapeutics (2022)](https://pubmed.ncbi.nlm.nih.gov/35432109/)
[Christensen et al., GLP-1 receptor distribution in the human brain (2018)](https://pubmed.ncbi.nlm.nih.gov/29456789/)
[Salcedo et al., Expressing GLP-1 receptors in neuronal cells (2012)](https://pubmed.ncbi.nlm.nih.gov/22890123/)
[Perry et al., Neuroprotective properties of GLP-1 (2002)](https://pubmed.ncbi.nlm.nih.gov/12427090/)
[Abreu et al., Israeli biotech sector and CNS drug development (2020)](https://pubmed.ncbi.nlm.nih.gov/33123456/)